NCT03954626View on ClinicalTrials.gov

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 7, 2019

Primary Completion Date

July 9, 2019

Study Completion Date

July 31, 2019

Conditions
Age-Related Macular DegenerationMacular DegenerationWet Macular DegenerationRetinal DegenerationRetinal DiseasesEye Diseases
Interventions
BIOLOGICAL

brolucuzumab 6 mg IVT

Single intravitreal injection (IVT) of brolucizumab 6 mg

Trial Locations (3)

79606

Novartis Investigative Site, Abilene

85014

Novartis Investigative Site, Phoenix

00612

Novartis Investigative Site, Arecibo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY